BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18181342)

  • 1. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.
    Charoentum C; Thongprasert S; Chewasakulyong B; Euathrongchit J; Sorraritchingchai S; Munprakan S
    J Med Assoc Thai; 2007 Nov; 90(11):2506-12. PubMed ID: 18181342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.
    Mok TS; Ho S; Chan G; Ho WM; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Lee Y; Lam KC
    J Thorac Oncol; 2007 Sep; 2(9):838-44. PubMed ID: 17805062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
    Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis ; Kremos S; Georgoulias V
    Ann Oncol; 2000 Jun; 11(6):757-60. PubMed ID: 10942068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
    Fujimoto N; Kiura K; Takigawa N; Fujiwara Y; Toyooka S; Umemura S; Tabata M; Ueoka H; Tanimoto M
    Acta Med Okayama; 2010 Feb; 64(1):33-7. PubMed ID: 20200582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
    J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.
    Molina JR; Nikcevich D; Hillman S; Geyer S; Drevyanko T; Jett J; Verdirame J; Tazelaar H; Rowland K; Wos E; Kutteh L; Nair S; Fitch T; Flynn P; Stella P; Adjei AA
    Cancer Invest; 2006; 24(4):382-9. PubMed ID: 16777690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
    Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
    Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
    Mattson K; Vansteenkiste J; Stupp R; Bargetzi M; Saarinen A; Jekunen A; Fillet G; Teixeira M; Gatzemeier U; Olivares R; Soussan-Lazard K; Bérille J
    Anticancer Drugs; 2000 Jan; 11(1):7-13. PubMed ID: 10757557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
    Zhang XR; Zhu YZ; Xiu QY; Han FC; Liu DQ; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):777-9. PubMed ID: 17366795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study.
    Abou-Mourad Y; Otrock ZK; Makarem JA; Kattan JG; Farhat FS; Jalloul R; Mokaddem WT; Ghosen MG; Taher AT; Chehal AA; Shamseddine AI
    J Med Liban; 2008; 56(1):16-21. PubMed ID: 19534086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.